RE: Watchlist - Investor method
CYTR is attempting a Stage 2A breakout on positive news for a new cancer drug they are developing called Aldoxorubicin. It had a massive spike in volume, 17 times the weekly average, relative performance has moved back above the zero line once more, and it's cleared weekly ichmoku cloud resistance. Attached are the charts.
isatrader
Fate does not always let you fix the tuition fee. She delivers the educational wallop and presents her own bill - Reminiscences of a Stock Operator.
Fate does not always let you fix the tuition fee. She delivers the educational wallop and presents her own bill - Reminiscences of a Stock Operator.